Mylan (Nasdaq: MYL) issued the following statement regarding Teva's (NYSE: TEVA) announcement of its entry into an agreement to acquire ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments Mergers and Acquisitions

Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics July 28, 2015 9:23 AM Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale July 28, 2015 9:13 AM Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement July 28, 2015 8:19 AM Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO July 28, 2015 8:12 AM Mylan's (MYL) Price Target Reduced to $65 at Deutsche BankJuly 27, 2015 2:34 PM Teva Pharma (TEVA) PT Raised to $74 at Maxim Group on Deal for Allergan's Generic Drug BusinessJuly 27, 2015 11:10 AM Cowen Downgrades Mylan (MYL) to Market PerformJuly 27, 2015 7:50 AM Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug UnitJuly 27, 2015 6:42 AM Teva Pharma (TEVA) Ends Effort to Acquire Mylan (MYL)July 27, 2015 6:07 AM Teva Withdraws Proposal to Acquire MylanJuly 27, 2015 4:31 AM Teva Pharma (TEVA) Nears Deal to Acquire Allergan's (AGN) Generic-Drug BusinessJuly 26, 2015 5:23 PM Mylan Schedules Second Quarter 2015 Financial Results Conference Call and Live WebcastJuly 24, 2015 3:28 PM Consumer Reports Negative on Teva Pharma (TEVA), Mylan (MYL) DealJuly 24, 2015 2:56 PM Form 8-K Mylan N.V. For: Jul 23July 23, 2015 5:19 PM